Medtronic begins pacemaker trials
This article was originally published in Clinica
Medtronic has begun European trials of its new Kappa 400 pacemaker. Dual-chamber devices have been implanted in patients in Italy and Denmark. A single-chamber version will also be evaluated in the 50-patient trial. Medtronic spokesman Dick Reid says data from a separate trial of a similar but larger device will be used for seeking regulatory approvals, although the larger pacemaker will probably not be marketed.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.